Cargando…

Inflammatory markers and long term hematotoxicity of holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial peptide receptor radionuclide therapy

PURPOSE: In patients with neuroendocrine tumor liver metastases, additional tumor reduction can be achieved by sequential treatment with [(166)Ho]-radioembolization after peptide receptor radionuclide therapy (PRRT). The aim of this study was to analyze hematotoxicity profiles, (i.e. lymphocyte and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ebbers, Sander C., Brabander, Tessa, Tesselaar, Margot E. T., Hofland, Johannes, Braat, Manon N. G. J. A., Wessels, Frank J., Barentsz, Maarten W., Lam, Marnix G. E. H., Braat, Arthur J. A. T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811020/ https://www.ncbi.nlm.nih.gov/pubmed/35107642 http://dx.doi.org/10.1186/s13550-022-00880-4

Ejemplares similares

Holmium-166 Radioembolization: Current Status and Future Prospective
por: Stella, Martina, et al.
Publicado: (2022)

Automatic healthy liver segmentation for holmium-166 radioembolization dosimetry
por: Stella, Martina, et al.
Publicado: (2023)

Gamma camera characterization at high holmium-166 activity in liver radioembolization
por: Stella, Martina, et al.
Publicado: (2021)

(166)Holmium–(99)(m)Technetium dual-isotope imaging: scatter compensation and automatic healthy-liver segmentation for (166)Holmium radioembolization dosimetry
por: Stella, Martina, et al.
Publicado: (2022)

Quality of life in patients with liver tumors treated with holmium-166 radioembolization
por: van Roekel, Caren, et al.
Publicado: (2019)

Use of an anti-reflux catheter to improve tumor targeting for holmium-166 radioembolization—a prospective, within-patient randomized study
por: van Roekel, Caren, et al.
Publicado: (2020)

Dose finding study for unilobar radioembolization using holmium-166 microspheres to improve resectability in patients with HCC: the RALLY protocol
por: Andel, Daan, et al.
Publicado: (2023)

Radioembolization-Induced Changes in Hepatic [(18)F]FDG Metabolism in Non-Tumorous Liver Parenchyma
por: Braat, Manon N., et al.
Publicado: (2022)

The Evolving Role of Radioembolization in the Treatment of Neuroendocrine Liver Metastases
por: Ramdhani, Khalil, et al.
Publicado: (2022)

Accuracy of SPECT/CT‐based lung dose calculation for Holmium‐166 hepatic radioembolization before OSEM convergence
por: van Nierop, Bastiaan J., et al.
Publicado: (2018)

Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial
por: Smits, Maarten LJ, et al.
Publicado: (2010)

The superior predictive value of (166)Ho-scout compared with (99m)Tc-macroaggregated albumin prior to (166)Ho-microspheres radioembolization in patients with liver metastases
por: Smits, Maarten L. J., et al.
Publicado: (2019)

Holmium-166 Transarterial Radioembolization for the Treatment of Intrahepatic Cholangiocarcinoma: A Case Series
por: Vermeulen, Sim, et al.
Publicado: (2023)

Safety analysis of holmium-166 microsphere scout dose imaging during radioembolisation work-up: A cohort study
por: Braat, Arthur J. A. T., et al.
Publicado: (2017)

Transarterial Radioembolization Planning and Treatment with Microspheres Containing Holmium-166: Determination of Renal and Intestinal Radionuclide Elimination, Effective Half-Life, and Regulatory Aspects
por: Kühnel, Christian, et al.
Publicado: (2022)

Radioembolization with (90)Y Resin Microspheres of Neuroendocrine Liver Metastases After Initial Peptide Receptor Radionuclide Therapy
por: Braat, A. J. A. T., et al.
Publicado: (2019)

Radionuclide therapy in the time of COVID-19
por: Brabander, Tessa, et al.
Publicado: (2020)

Surefire infusion system versus standard microcatheter use during holmium-166 radioembolization: study protocol for a randomized controlled trial
por: van den Hoven, Andor F., et al.
Publicado: (2016)

The physics of radioembolization
por: Bastiaannet, Remco, et al.
Publicado: (2018)

Gallium-68-somatostatin receptor PET/CT parameters as potential prognosticators for clinical time to progression after peptide receptor radionuclide therapy: a cohort study
por: Ebbers, Sander C., et al.
Publicado: (2021)

The Efficacy of Coil Embolization to Obtain Intrahepatic Redistribution in Radioembolization: Qualitative and Quantitative Analyses
por: Alsultan, Ahmed A., et al.
Publicado: (2019)

Simultaneous (166)Ho/(99m)Tc dual-isotope SPECT with Monte Carlo-based downscatter correction for automatic liver dosimetry in radioembolization
por: van Rooij, R., et al.
Publicado: (2020)

Percutaneous Sclerotherapy of Renal Cysts with a Beta-Emitting Radionuclide, Holmium-166-chitosan Complex
por: Kim, Joo Hee, et al.
Publicado: (2004)

A Clinical Guide to Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE in Neuroendocrine Tumor Patients
por: Becx, Morticia N., et al.
Publicado: (2022)

Study Protocol: Adjuvant Holmium-166 Radioembolization After Radiofrequency Ablation in Early-Stage Hepatocellular Carcinoma Patients—A Dose-Finding Study (HORA EST HCC Trial)
por: Hendriks, Pim, et al.
Publicado: (2022)

Hepatobiliary scintigraphy may improve radioembolization treatment planning in HCC patients
por: Braat, Manon N. G. J. A., et al.
Publicado: (2017)

Additional hepatic (166)Ho-radioembolization in patients with neuroendocrine tumours treated with (177)Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial)
por: Braat, Arthur J. A. T., et al.
Publicado: (2018)

Clinical Results of Transarterial Radioembolization (TARE) with Holmium-166 Microspheres in the Multidisciplinary Oncologic Treatment of Patients with Primary and Secondary Liver Cancer
por: Drescher, Robert, et al.
Publicado: (2023)

Peptide Receptor Radionuclide Therapy
por: Hofland, Johannes, et al.
Publicado: (2022)

Hepatic Radioembolization as a Bridge to Liver Surgery
por: Braat, Arthur J. A. T., et al.
Publicado: (2014)

Verification Study of Residual Activity Measurements After Yttrium-90 Radioembolization with Glass Microspheres
por: Ebbers, S. C., et al.
Publicado: (2020)

Radioembolization With Holmium-166 Polylactic Acid Microspheres: Distribution of Residual Activity in the Delivery Set and Outflow Dynamics During Planning and Treatment Procedures
por: Drescher, Robert, et al.
Publicado: (2021)

Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial)
por: Ebbers, Sander C., et al.
Publicado: (2020)

Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy
por: Minczeles, N.S., et al.
Publicado: (2021)

Feasibility of imaging (90)Y microspheres at diagnostic activity levels for hepatic radioembolization treatment planning
por: Kunnen, Britt, et al.
Publicado: (2020)

MRI-based biodistribution assessment of holmium-166 poly(L-lactic acid) microspheres after radioembolisation
por: van de Maat, Gerrit H., et al.
Publicado: (2012)

Intraprocedural MRI-based dosimetry during transarterial radioembolization of liver tumours with holmium-166 microspheres (EMERITUS-1): a phase I trial towards adaptive, image-controlled treatment delivery
por: Roosen, Joey, et al.
Publicado: (2022)

The various therapeutic applications of the medical isotope holmium-166: a narrative review
por: Klaassen, Nienke J. M., et al.
Publicado: (2019)

Intratumoral injection of radioactive holmium-166 microspheres in recurrent head and neck squamous cell carcinoma: preliminary results of first use
por: Bakker, Robbert C., et al.
Publicado: (2018)

Salvage peptide receptor radionuclide therapy with [(177)Lu-DOTA,Tyr(3)]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours
por: van der Zwan, W. A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4n93pk20lkr6tbrejjo6a6gi14